VTRNA2-1在特应性皮炎患者外周血T淋巴细胞中的表达分析

doi:10.3969/j.issn.1006-6233.2021.12.011

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1429 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the expression characteristics of fornix ribonucleic acid 2-1 (VTRNA2-1) in peripheral blood T lymphocytes of patients with Atopic Dermatitis (AD) and its clinical significance. Methods: AD patients (AD group, 50 cases) and healthy controls (control group, 30 cases) admitted to the dermatology department of our hospital from January 2018 to December 2020 were selected as the research subjects. AD patients were divided according to the dermatitis score index (SCORAD) into mild AD group, moderate AD group, and severe AD group. Peripheral blood of all patients was collected to isolate CD4⁺ T lymphocytes, detect the expression of VTRNA2-1 gene in CD4⁺ T lymphocytes by real-time fluorescent quantitative PCR, and compare the differences of VTRNA2-1 levels between each group; Western blot and immunoprecipitation experiments were used to analyze the level of VTRNA2-1 protein and its direct-acting proteins. Results: The expression level of VTRNA2-1 gene in CD4⁺ T lymphocytes of patients in AD group was significantly higher than that in control group (P<0.05); the level of VTRNA2-1 in the mild AD group and the moderate AD group was significantly lower than that of the severe AD group, while the VTRNA2-1 level of the mild AD group was significantly lower than that of the moderate AD group (P<0.05); VTRNA2-1 gene expression level was significantly positively correlated with SCORAD score (r=0.619, P<0.05); co-immunoprecipitation experiments confirmed that VTRNA2-1 exerts biological functions through specific binding to protein kinase R (PKR). Conclusion: VTRNA2-1 gene is highly expressed in CD4⁺ T lymphocytes of patients with AD. Increased expression of VTRNA2-1 may aggravate the severity of clinical symptoms in patients. The mechanism may be through activation of PKR, which may play a role in the pathological process of AD Regulation.

Key words： VTRNA2-1 Atopic dermatitis T lymphocytes Protein kinase R

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WAN Mengjie
	WANG Wei
	FAN Xiuhong

Cite this article:

WAN Mengjie,WANG Wei,FAN Xiuhong. Expression Analysis of VTRNA2-1 in Peripheral Blood T Lymphocytes of Patients with Atopic Dermatitis[J]. HeBei Med, 2021, 27(12): 1987-1990.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2021.12.011 OR http://www.hbyxzzs.cn/EN/Y2021/V27/I12/1987

[1] 叶城斌,邹颖.不同国家及地区特应性皮炎治疗指南的比较[J].中国皮肤性病学杂志,2020,34(11):1331~1336,1340.
[2] Yum H Y,Kim H H,Kim H J,et al.Current management of moderate-to-severe atopic dermatitis:a survey of allergists,pediatric allergists and dermatologists in korea[J].Allergy Asthma Immunol Res,2018,10(3):253~259.
[3] 林欢儿,李孜怡,彭静,等.中医药治疗特应性皮炎研究进展[J].辽宁中医药大学学报,2019,21(11):29~32.
[4] 郭远,蔡羽恬,郭宁宁,等.特应性皮炎的免疫机制及Dupilumab治疗研究进展[J].中国麻风皮肤病杂志,2018,34(2):125~128.
[5] Lee K S,Shin S,Cho E,et al.nc886,a non-coding RNA,inhibits UVB-induced MMP-9 and COX-2 expression via the PKR pathway in human keratinocytes[J].Biochem Biophys Res Commun,2019,512(4):647~652.
[6] Fort R S,Garat B,José R S-S,et al.vtRNA2-1/nc886 produces a small RNA that contributes to its tumor suppression action through the microRNA pathway in prostate cancer[J].Noncoding RNA,2020,6(1):7.
[7] Chajra H,Garandeau D,Delluc C,et al.434 Novel anti-ageing function discovered in skin for the long non coding RNA nc886[J].Journal of Investigative Dermatology,2019,139(5):75.
[8] 王建琴.中国特应性皮炎诊疗指南(2020版)解读[J].皮肤性病诊疗学杂志,2020,27(5):359~361.
[9] 朱杰,陈君.中药熏洗联合妙思乐润肤霜治疗儿童特应性皮炎临床研究[J].新中医,2020,52(6):85~87.
[10] 赵一丁,杨洁,闫小宁,等.特应性皮炎不同中医证型外周血T细胞亚群及其相关细胞因子表达的研究[J].中国中医基础医学杂志,2018,24(1):69~72.
[11] 万梦婕,邱湘宁,陆前进.VTRNA2-1在系统性红斑狼疮患者B细胞中的高表达及其意义[J].中南大学学报(医学版),2020,45(2):123~127.
[12] Sallustio F,Serino G,Cox S N 3,et al.Aberrantly methylated DNA regions lead to low activation of CD4⁺ T-cells in IgA nephropathy[J].Clin Sci (Lond),2016,130(9):733~746.
[13] Fort R S,Mathó C,Geraldo M V,et al.Nc886 is epigenetically repressed in prostate cancer and acts as a tumor suppressor through the inhibition of cell growth[J].BMC Cancer,2018,18(1):127.
[14] Yu M C,Lee C W,Lin C H,et al.Differential hypermethylation of the VTRNA2-1 promoter in hepatocellular carcinoma as a prognostic factor:Tumor marker prognostic study[J].International Journal of Surgery,2020,79(2):282~289.
[15] Ewelina G ,Liza L ,Munazza Q ,et al.The noncoding RNA nc886 regulates PKR signaling and cytokine production in human cells.[J].Journal of immunology,2019,202(1):131~141.